NeuroSearch A/S shrugged off disappointment in the clinic last week - namely, the failure of ABT-894 in a Phase II trial in diabetic neuropathic pain - with a three-year central nervous system drug discovery alliance with Eli Lilly and Co. that has the potential to grow to blockbuster proportions.